|ZFIN ID: ZDB-PERS-990223-17|
BIOGRAPHY AND RESEARCH INTERESTS
Znomics is employing breakthrough genetic advances with zebrafish to improve and speed human drug discovery. The Znomics discovery platform is based on two key technologies: 1) development of disease models and assays in zebrafish that are suitable for high-throughput in vivo drug discovery and 2) for drug target discovery, a new retroviral insertional mutagenesis system that allows for mutation of all of the 40,000+ zebrafish genes followed by rapid recovery of genes of interest. This tagged mutant gene library ('ZeneMark™ Library') will be the first of its kind in any vertebrate. With this set of lesions, company scientists can then identify all genes that contribute to a particular disease-related process.
Song, Y., Golling, G., Thacker, T.L., and Cone, R.D. (2003) Agouti-related protein (AGRP) is conserved and regulated by metabolic state in the zebrafish, Danio rerio. Endocrine. 22(3):257-266
Golling, G., Amsterdam, A., Sun, Z., Antonelli, M., Maldonado, E., Chen, W., Burgess, S., Haldi, M., Artzt, K., Farrington, S., Lin, S.Y., Nissen, R.M., and Hopkins, N. (2002) Insertional mutagenesis in zebrafish rapidly identifies genes essential for early vertebrate development. Nature Genetics. 31(2):135-140
Chen, W.B., Burgess, S., Golling, G., Amsterdam, A., and Hopkins, N. (2002) High-throughput selection of retrovirus producer cell lines leads to markedly improved efficiency of germ line-transmissible insertions in zebra fish. Journal of virology. 76(5):2192-2198
Amsterdam, A., Burgess, S., Golling, G., Chen, W., Sun, Z., Townsend, K., Farrington, S., Haldi, M., and Hopkins, N. (1999) A large-scale insertional mutagenesis screen in zebrafish. Genes & Development. 13(20):2713-2724